The Frontier Atlas
VECTOR: PHOTOBIOMODULATIONToronto, CanadaVielight Inc.

Vielight

Intranasal and transcranial photobiomodulation devices (around $1,799) delivering near-infrared light to brain tissue — the entry in this region with the strongest independent research base.

3 SOURCES CITED
CLAIMED — WHAT THE MAKER STATES
  • The maker states its devices deliver non-ionizing near-infrared light to stimulate cellular processes, particularly mitochondrial ATP production, for improved cognition, memory, focus, and immunity.
  • The site cites 30+ published studies, including a UCSF fMRI study on the Neuro Gamma device and a study in Nature Scientific Reports on EEG neuromodulation.
  • Clinical trials are referenced across conditions including traumatic brain injury, Alzheimer's, and autism; the flagship Neuro Gamma is priced around $1,799.
CITED SOURCES — NAMED, NOT ADJUDICATED
UCSF fMRI study on Vielight Neuro Gamma

A named, institution-affiliated study — independently checkable, and stronger than most citations in this region.

Nature Scientific Reports (EEG neuromodulation study)

A peer-reviewed journal citation — verifiable, though effect size and replication remain open.

Photobiomodulation (PBM) research base

PBM/low-level light therapy has a genuine and growing peer-reviewed literature independent of this company — the mechanism is not fringe, though device-specific efficacy is still being established.

EVERY SOURCE IS NAMED SO YOU CAN VERIFY IT YOURSELF. NAMING A SOURCE IS NOT ENDORSING IT.

OPEN QUESTIONS — NOT YET RESOLVED
  • The device-specific clinical trials (Alzheimer's, TBI) — what stage are they at, and what were the actual effect sizes versus sham controls?
  • How much of the cited '30+ studies' base is on Vielight devices specifically versus photobiomodulation as a general category?
  • What is the durability of any cognitive effect after a treatment course ends?
FIELD NOTE

Vielight is the closest thing in this region to a device with genuine, independently-cited clinical footing — photobiomodulation crossed from fringe into peer-reviewed journals over the past decade, and Vielight is among the most study-forward makers.

The open questions here are about dosage, effect size, and durability — not whether the underlying mechanism exists at all, which distinguishes it from most other entries in this region.

SOURCE: vielight.com (scraped 2026-07-09)

THE DATA POINT — WHAT THE ATLAS IS COLLECTING

Which protocol, how long, and what cognitive measure actually moved?

Institution-affiliated pilot data is published; the Atlas is collecting longitudinal real-world user protocols and outcomes.

Report from the field →